prnewswire.comOct 28$PGEN

Precigen to Announce Third Quarter 2026 Financial Results and Provide Business Updates on November 4

Precigen, Inc. (PGEN) will release Q3 2026 financial results and business updates on November 4, 2026, hosting a conference call at 4:30 PM ET. The company focuses on precision medicines for immuno-oncology, autoimmune disorders, and infectious diseases, with a pipeline including PAPZIMEOS for recurrent respiratory papillomatosis.

Original reporting

prnewswire.com

Published Oct 28, 2026, 8:05 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 28, 2026, 8:09 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefEarnings

Primary signal

$PGEN

Neutral

high confidence

Mentioned

$PGEN

Relevance

4/10

AlphAI data visualization · based on prnewswire.com

Decision brief

The 30-second read

$PGENNeutralLow

Why it matters

The press release is a routine earnings‑date announcement with no new financial metrics, offering limited immediate trading insight.

Market read

The article provides a schedule for an upcoming earnings release, which may generate modest pre‑release positioning but lacks actionable information.

What to watch

Potential regulatory updates or trial data releases before the earnings date could materially shift sentiment.

Relevance 4/10Novelty 2/10Timing: Nov 4 release

Background

Precigen is a commercial‑stage biopharma focused on precision medicines in immuno‑oncology, autoimmune disorders, and infectious diseases.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$PGENNeutralHigh confidence

Context

Precigen announced it will release its Q3 2026 financial results and business updates on November 4, 2026.

Expected impact

likely modest pressure or volatility as traders position ahead of the results

Evidence & confidence

No new financial numbers are disclosed; the market will react primarily to the upcoming earnings, which may cause limited pre‑release positioning.

Market effects

Sector

None disclosed; the announcement does not affect broader biotech sector trends.

Regional

Limited to U.S. investors tracking Precigen.

Global

Minimal; only relevant to shareholders and analysts covering the company.

Counterpoint

What could challenge this read

If the market overreacts to the date announcement, a contrarian could consider short positions anticipating a muted earnings surprise.

Key entities

company
Precigen, Inc.
Biopharmaceutical company announcing its Q3 2026 results.

Read at source ← All news

$PGENMedAI 8/10

Precigen Sinks 26% as Inovio Wins FDA Approval for Papzimeos Rival Days Before Earnings

Precigen (PGEN) shares dropped 26% after Inovio (INO) received FDA approval for Voceryq, a rival to Precigen's Papzimeos. Voceryq offers easier dosing, though Papzimeos showed stronger trial results. Precigen reports Q3 earnings on November 4, with analysts expecting $236M in 2026 revenue.

finance.yahoo.comNov 2

$PGENHighAI 9/10

PGEN Stock Crashes Premarket: Retail Sees Buyout Opening As Inovio Rival Crashes The Party Before Earnings

Precigen (PGEN) shares dropped 20% premarket after Inovio's (INO) FDA-approved rival treatment, Voceryq, challenged Papzimeos. PGEN reported $53.1M Q2 revenue. Retail investors remain optimistic about a potential buyout. Voceryq expects shipments in 60 days, with full deployment in early 2027. Clinical trials showed higher surgery-free rates for Papzimeos (51%) vs. Voceryq (27%).

finance.yahoo.comNov 2

$INOHighAI 9/10

FDA Grants Accelerated Approval to Inovio's DNA Immunotherapy Voceryq; Precigen Shares Plunge 27% After Hours

FDA granted accelerated approval to Inovio's (INO) DNA immunotherapy Voceryq for recurrent respiratory papillomatosis. Inovio shares surged 300% after hours, while Precigen's (PGEN) shares dropped 27% on market competition concerns. Voceryq is the first plasmid DNA-based immunotherapy approved in the U.S. and the second treatment for the disease.

finance.biggo.comOct 30

$PGENMedAI 8/10

Precigen (PGEN) Gets FDA Recognition. Can it Cut the Cost of Developing New Drugs?

Precigen (PGEN) received FDA Platform Technology Designation for AdenoVerse, the technology behind PAPZIMEOS. The designation may reduce development costs for future drugs, including PRGN-2009, an investigational cancer treatment. Management expects benefits but has not quantified cost savings or timelines. The FDA's draft guidance outlines potential benefits, but Precigen must provide supporting evidence for reuse of prior data. Hedge fund sentiment showed a slight decrease in holdings.

insidermonkey.comSep 29

$PGENHighAI 8/10

Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform

Precigen, Inc. (PGEN) announced that the FDA granted platform technology designation to its AdenoVerse® immunotherapeutic platform, used in its commercial product PAPZIMEOS®. This designation may accelerate the development of future therapies by leveraging existing data and reducing duplicative work. The company's CEO highlighted the potential benefits for its clinical portfolio, including PRGN-2009 for HPV-associated cancers.

prnewswire.comSep 21

$MRNAHighAI 9/10

After Moderna’s Big News, Here Are Three Biotechs to Watch

Moderna (MRNA) and Merck (MRK) rose sharply after positive Phase 3 trial data for a skin cancer therapy. Biotech sector, up 40% YTD, saw gains. Aurinia (AUPH) settled litigation with Teva (TEVA), removing uncertainty. Ocular (OCUL) received positive analyst ratings. Precigen (PGEN) reported strong Q2 revenue and expects cash flow breakeven by year-end.

pro.thestreet.comAug 21